Drug Approval | May 11, 2024
Strides receives USFDA approval for Sevelamer Carbonate Tablets
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company is committed to address this observation comprehensively within stipulated time
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
The product is used to treat amyotrophic lateral sclerosis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subscribe To Our Newsletter & Stay Updated
